Amentoflavone and cancer: mechanistic insights and translational perspectives
Frontiers in Oncology · 30.07.2026 · 16
DOI: 10.3389/fonc.2026.1813172 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 30.07.2026. Verfasst von Hiroki Hashida und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Hanwa Memorial Hospital, Osaka, Japan. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Amentoflavone (AF) is a naturally occurring biflavonoid isolated from multiple medicinal plants and widely studied for anti-inflammatory and antioxidant activities. In oncology, AF has emerged as a pleiotropic small molecule that modulates interconnected signaling axes rather than a single node. Preclinical studies indicate that AF attenuates PI3K/Akt/mTOR signaling and NF-κB–dependent survival programs, disrupts Wnt/β-catenin–linked epithelial–mesenchymal transition (EMT), and modulates MAPK cascades to promote apoptosis and cell-cycle arrest. AF also interferes with pro-angiogenic signaling and VEGF-driven neovascularization. Across diverse cancer models, these activities translate into reduced proliferation, enhanced apoptosis, suppression of invasion/EMT, and inhibition of tumor-associated angiogenesis. However, translation remains limited by poor aqueous solubility, low oral exposure, and incomplete exposure–response and safety characterization. Recent drug delivery approaches (polymeric micelles, mixed nanomicelles, DSPE-PEG micelles) and rational combination strategies provide practical routes to improve systemic exposure and revisit AF in combination regimens. This review integrates mechanistic and tumor-specific evidence with a clear distinction between direct target binding and downstream pathway readouts, quantitative in vitro / in vivo endpoints, an expanded reference list using verifiable sources, and priorities for pharmacokinetic optimization, toxicity evaluation, and biomarker-guided early-phase development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Hanwa Memorial Hospital, Osaka, Japan.
Zitieren
APA
Hashida, H., Kobayashi, A., Akagami, M., Okamoto, T., & Tanaka, H. (2026). Amentoflavone and cancer: mechanistic insights and translational perspectives. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1813172
Vancouver
Hashida H, Kobayashi A, Akagami M, Okamoto T, Tanaka H. Amentoflavone and cancer: mechanistic insights and translational perspectives. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1813172
BibTeX
@article{Hashida2026,
author = {Hashida, Hiroki and Kobayashi, Atsushi and Akagami, Masatoshi and Okamoto, Tomohiro and Tanaka, Hirokazu},
title = {Amentoflavone and cancer: mechanistic insights and translational perspectives},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1813172}
}
EUVIMED